Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, baricitinib improved the resolution of arthritis or rash in patients with systemic lupus erythematosus, but outcomes for skin involvement like alopecia were not reported.

This article reviews the differences in inflammatory processes between alopecia universalis and atopic dermatitis, focusing on type 1 and type 2 immune responses, but it reports no new results.

This study suggests that the emulsion extract of brevilin A from Centipeda minima may stimulate hair regrowth in individuals with mild to moderate vertex balding by inhibiting JAK3.

This study observed that Epigallocatechin-3-gallate (EGCG) can inhibit phosphorylation of STAT1 and reduce a specific subset of immune cells in vitro and ex vivo, suggesting a potential role in maintaining immune privilege in alopecia areata.

This case report describes a 40-year-old Indian male with sclerosing cholangitis whose skin lesions and liver function improved following surgical treatment.

This study found that human hematopoietic mesenchymal stem cells increased the viability and migration of human outer root sheath cells in an in vitro alopecia areata model, involving Wnt/β-catenin and JAK/STAT pathways.

This review discusses the JAK/STAT signaling pathway's role in immune-mediated skin diseases and examines the efficacy and safety of JAK inhibitors for treating vitiligo and alopecia areata, but reports no new clinical results.

This review discusses the development of Janus kinase inhibitors for dermatologic diseases and reports no new results; the authors note the need for further research on their efficacy and safety.

This study found that Ifidancitinib, a JAK1/3 inhibitor, significantly promoted hair regrowth and reduced inflammation in a mouse model of alopecia areata by decreasing pathogenic T cell activity and inducing T cell exhaustion.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

This study suggests that although data on JAK inhibitors for treating LPP and FFA is mainly from retrospective studies and case reports, these inhibitors may offer a new treatment option, particularly for challenging cases.

In this study of seven randomized clinical trials, JAK inhibitors were associated with improved hair regrowth outcomes in alopecia areata patients compared to placebo, with oral administration being more effective than external application, though longer trials are needed to confirm safety and effectiveness.

This review suggests that oral Janus kinase inhibitors are a promising treatment for alopecia areata in adults, showing significant hair regrowth with fewer side effects than conventional treatments, while PDE-4 inhibitors and biologics show limited efficacy.

Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.

This source reports that recent research highlights the effectiveness and tolerability of oral JAK inhibitors for treating moderate to severe alopecia areata, although further placebo-controlled studies are needed to confirm their long-term safety and efficacy.

This article is a Letter to the Editor discussing rebound effects associated with JAK inhibitor use in treating alopecia areata and reports no new clinical results.

In this case report, the authors describe a child with treatment-resistant alopecia areata who successfully responded to leflunomide and anthralin, proposing this combination as a potentially cost-effective alternative for managing recalcitrant cases by possibly inhibiting the JAK/STAT pathway.

This research highlights that JAK inhibitors, such as baricitinib, may effectively reverse symptoms of alopecia areata by targeting specific immune pathways, though safety and efficacy require further investigation.

In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.

This study found that epidermal stem cell-specific Jag1 expression levels are crucial for effective wound healing and scar reduction, and porcine acellular dermal matrix treatment enhances this process in mice by boosting Notch/Jagged1 signaling.

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

This article is a letter to the editor discussing positive Jacquet's sign in traction alopecia and provides no new research results.

This study found that oral administration of Laminaria japonica and Cistanche tubulosa extracts may improve hair regrowth in mice, comparable to the effects of 3% Minoxidil, potentially due to their anti-inflammatory properties.

This source reports that tofacitinib and ruxolitinib showed potential efficacy and acceptable safety profiles in treating various autoimmune disorders, including alopecia areata and psoriasis, based on a review of clinical studies, while recommending physicians consider the individual risks and benefits.

In this study, researchers found that disrupting EGFR signaling in mice led to increased inflammation and hair follicle damage but that inhibiting the JAK-STAT1 pathway could restore hair growth and skin function.

This review discusses JAK inhibitors as promising new treatments for various chronic dermatologic conditions, including some recent drug approvals, and reports no new clinical results.

This study found that Rumex japonicus Houtt. root extract promoted hair growth by enhancing cell proliferation and preventing apoptosis in human dermal papilla cells and HaCaT cells, as well as in a mouse model.

This study found that KRT6A expression increases after epidermal barrier disruption, worsening skin inflammation in disease conditions, and suggests that targeting KRT6A could offer a new treatment approach for inflammatory skin diseases linked to epidermal dysfunction.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.